113 related articles for article (PubMed ID: 18587567)
1. No role for the CYP3A5*3 polymorphism in intestinal and hepatic metabolism of midazolam.
Tomalik-Scharte D; Doroshyenko O; Kirchheiner J; Jetter A; Lazar A; Klaassen T; Frank D; Wyen C; Fätkenheuer G; Fuhr U
Eur J Clin Pharmacol; 2008 Oct; 64(10):1033-5. PubMed ID: 18587567
[No Abstract] [Full Text] [Related]
2. Effects of the CYP oxidoreductase Ala503Val polymorphism on CYP3A activity in vivo: a randomized, open-label, crossover study in healthy Chinese men.
Yang G; Fu Z; Chen X; Yuan H; Yang H; Huang Y; Ouyang D; Tan Z; Tan H; Huang Z; Zhou H
Clin Ther; 2011 Dec; 33(12):2060-70. PubMed ID: 22177374
[TBL] [Abstract][Full Text] [Related]
3. Urinary metabolic markers reflect on hepatic, not intestinal, CYP3A activity in healthy subjects.
Lee S; Lee Y; Kim AH; Yoon S; Lee J; Ji SC; Yoon SH; Lee S; Yu KS; Jang IJ; Cho JY
Drug Metab Pharmacokinet; 2021 Feb; 36():100374. PubMed ID: 33348239
[TBL] [Abstract][Full Text] [Related]
4. Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women.
Floyd MD; Gervasini G; Masica AL; Mayo G; George AL; Bhat K; Kim RB; Wilkinson GR
Pharmacogenetics; 2003 Oct; 13(10):595-606. PubMed ID: 14515058
[TBL] [Abstract][Full Text] [Related]
5. Sex-dependent differences in cytochrome P450 3A activity as assessed by midazolam disposition in humans: a meta-analysis.
Hu ZY; Zhao YS
Drug Metab Dispos; 2010 May; 38(5):817-23. PubMed ID: 20164111
[TBL] [Abstract][Full Text] [Related]
6. Characterization of Intestinal and Hepatic CYP3A-Mediated Metabolism of Midazolam in Children Using a Physiological Population Pharmacokinetic Modelling Approach.
Brussee JM; Yu H; Krekels EHJ; Palić S; Brill MJE; Barrett JS; Rostami-Hodjegan A; de Wildt SN; Knibbe CAJ
Pharm Res; 2018 Jul; 35(9):182. PubMed ID: 30062590
[TBL] [Abstract][Full Text] [Related]
7. Dose-dependent intestinal and hepatic first-pass metabolism of midazolam, a cytochrome P450 3A substrate with differently modulated enzyme activity in rats.
Higashikawa F; Murakami T; Kaneda T; Kato A; Takano M
J Pharm Pharmacol; 1999 Jan; 51(1):67-72. PubMed ID: 10197420
[TBL] [Abstract][Full Text] [Related]
8. Intestinal CYP3A4 and midazolam disposition in vivo associate with VDR polymorphisms and show seasonal variation.
Thirumaran RK; Lamba JK; Kim RB; Urquhart BL; Gregor JC; Chande N; Fan Y; Qi A; Cheng C; Thummel KE; Hall SD; Schuetz EG
Biochem Pharmacol; 2012 Jul; 84(1):104-12. PubMed ID: 22484315
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of human intestinal wall metabolism by macrolide antibiotics: effect of clarithromycin on cytochrome P450 3A4/5 activity and expression.
Pinto AG; Wang YH; Chalasani N; Skaar T; Kolwankar D; Gorski JC; Liangpunsakul S; Hamman MA; Arefayene M; Hall SD
Clin Pharmacol Ther; 2005 Mar; 77(3):178-88. PubMed ID: 15735612
[TBL] [Abstract][Full Text] [Related]
10. First-Pass CYP3A-Mediated Metabolism of Midazolam in the Gut Wall and Liver in Preterm Neonates.
Brussee JM; Yu H; Krekels EHJ; de Roos B; Brill MJE; van den Anker JN; Rostami-Hodjegan A; de Wildt SN; Knibbe CAJ
CPT Pharmacometrics Syst Pharmacol; 2018 Jun; 7(6):374-383. PubMed ID: 29745466
[TBL] [Abstract][Full Text] [Related]
11. Genotype-phenotype associations of cytochrome P450 3A4 and 3A5 polymorphism with midazolam clearance in vivo.
He P; Court MH; Greenblatt DJ; Von Moltke LL
Clin Pharmacol Ther; 2005 May; 77(5):373-87. PubMed ID: 15900284
[TBL] [Abstract][Full Text] [Related]
12. Daily honey consumption does not change CYP3A activity in humans.
Fetzner L; Burhenne J; Weiss J; Völker M; Unger M; Mikus G; Haefeli WE
J Clin Pharmacol; 2011 Aug; 51(8):1223-32. PubMed ID: 21148046
[TBL] [Abstract][Full Text] [Related]
13. Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers.
Yeh RF; Gaver VE; Patterson KB; Rezk NL; Baxter-Meheux F; Blake MJ; Eron JJ; Klein CE; Rublein JC; Kashuba AD
J Acquir Immune Defic Syndr; 2006 May; 42(1):52-60. PubMed ID: 16639344
[TBL] [Abstract][Full Text] [Related]
14. Effect of breviscapine on CYP3A metabolic activity in healthy volunteers.
Zhou X; Gao YY; Hu JY; Dong Y; Zhang HZ; Lai Y
Eur J Clin Pharmacol; 2018 Jan; 74(1):37-44. PubMed ID: 28986606
[TBL] [Abstract][Full Text] [Related]
15. Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping.
Lee JI; Chaves-Gnecco D; Amico JA; Kroboth PD; Wilson JW; Frye RF
Clin Pharmacol Ther; 2002 Dec; 72(6):718-28. PubMed ID: 12496753
[TBL] [Abstract][Full Text] [Related]
16. Hepatic and intestinal cytochrome P450 3A activity in cirrhosis: effects of transjugular intrahepatic portosystemic shunts.
Chalasani N; Gorski JC; Patel NH; Hall SD; Galinsky RE
Hepatology; 2001 Dec; 34(6):1103-8. PubMed ID: 11731998
[TBL] [Abstract][Full Text] [Related]
17. Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam.
Kharasch ED; Walker A; Isoherranen N; Hoffer C; Sheffels P; Thummel K; Whittington D; Ensign D
Clin Pharmacol Ther; 2007 Oct; 82(4):410-26. PubMed ID: 17554244
[TBL] [Abstract][Full Text] [Related]
18. CYP3A4 intron 6 C>T SNP (CYP3A4*22) encodes lower CYP3A4 activity in cancer patients, as measured with probes midazolam and erythromycin.
Elens L; Nieuweboer A; Clarke SJ; Charles KA; de Graan AJ; Haufroid V; Mathijssen RH; van Schaik RH
Pharmacogenomics; 2013 Jan; 14(2):137-49. PubMed ID: 23327575
[TBL] [Abstract][Full Text] [Related]
19. The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity.
Gorski JC; Vannaprasaht S; Hamman MA; Ambrosius WT; Bruce MA; Haehner-Daniels B; Hall SD
Clin Pharmacol Ther; 2003 Sep; 74(3):275-87. PubMed ID: 12966371
[TBL] [Abstract][Full Text] [Related]
20. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism.
Thummel KE; O'Shea D; Paine MF; Shen DD; Kunze KL; Perkins JD; Wilkinson GR
Clin Pharmacol Ther; 1996 May; 59(5):491-502. PubMed ID: 8646820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
